Investigational drug · Phase 3
FDY-5301
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myocardial Infarction, STEMI, Percutaneous Coronary Revascularization.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "FDY-5301"
First trial start
2022
May 2, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FDY-5301", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myocardial Infarction
- STEMI
- Percutaneous Coronary Revascularization
Approved drugs for the same conditions: Coronary artery disease and heart attack · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "FDY-5301" as an intervention, largest first.
- Evaluation in STEMI Patients Using FDY-5301Pivotal-lookingCompleted
Faraday Pharmaceuticals, Inc.Industry
NCT04837001 · 2,351 participants · Start May 2, 2022 · Primary completion Sep 3, 2025
Drug: FDY-5301 · For: Acute Myocardial Infarction; STEMI; Percutaneous Coronary Revascularization
Sites: Torrance, California; Jacksonville, Florida; Boston, Massachusetts · 52 sites in all
- A Study of Acute Myocardial Infarction Using FDY-5301Pivotal-lookingCompleted
Faraday Pharmaceuticals, Inc.Industry
NCT03470441 · 120 participants · Start Oct 27, 2017 · Primary completion Jul 14, 2018
Drug: FDY-5301 · For: Acute Myocardial Infarction; STEMI
Sites: Minneapolis, Minnesota; The Bronx, New York; Budapest, Hungary · 23 sites in all
Faraday Pharmaceuticals, Inc.Industry
NCT04430283 · 8 participants · Start Sep 20, 2021 · Primary completion Mar 4, 2022
Drug: FDY-5301 · For: ICU Acquired Weakness
Sites: Torrance, California; Gainesville, Florida; Boston, Massachusetts · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- FDY-5301: An Innovative Approach to The Treatment of Revascularization Coronary Injury.
Williams LE, Frishman WH · Cardiol Rev 2024
- A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI.
Adlam D, Zarebinski M, Uren NG, et al. · Int J Cardiol 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.